© 2024 SEISMIC TX. ALL RIGHTS RESERVED.
Cambridge, Mass., October 11, 2023 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will participate in several upcoming scientific and industry meetings in Q4 2023, highlighting the company’s proprietary approach to applying machine learning to biologics drug discovery for immunology, and its emerging pipeline of novel therapeutics to treat dysregulated adaptive immunity.
“We look forward to sharing our progress at upcoming scientific meetings, presenting on a range of topics that describe the innovation of our IMPACT platform to usher in a new era of immunology drug development that integrates machine learning, as well as the advancement of our preclinical programs,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D of Seismic Therapeutic. “Leveraging our IMPACT platform, we are building a pipeline of novel enzyme and antibody programs focused on addressing the unmet needs in autoimmune diseases to have a broad impact on patients.”
Details of the presentations and poster sessions by members of the Seismic team are as follows:
Thursday, October 12
QSP (Quantitative Systems Pharmacology) Summit
Presentation: Preclinical modeling of an IgG cleaving enzyme: A solution to a unique problem
Presenter: Alex Pellerin, PhD, Director of Preclinical Development
Time: 9:00 a.m. ET
Location: Cambridge, MA
Sunday, October 15
International Conference of the Inflammation Research Association
Keynote Address: New approaches for treating dysregulated adaptive immunity
Presenter: Jo Viney, PhD, President and Chief Executive Officer
Time: 6:30 p.m. MT
Location: Fort Collins, CO
Wednesday, November 15
PEGS Europe – Protein & Antibody Engineering Summit
Presentation: Integration of Machine Learning, Structural Biology, and Wet Lab Data to Augment Drug Discovery for Autoimmune Diseases
Presenter: Nathan Higginson-Scott, PhD, Chief Technology Officer
Session: Machine Learning for Protein Engineering, Part 1
Time: 5:30 p.m. Western European Time
Location: Lisbon, Portugal
Thursday, December 14 and Friday-Saturday, December 15-16
Antibody Engineering and Therapeutics
Presentation: Dual-cell Bidirectional (DcB) Antibodies for Targeting Multiple Inhibitory Pathways for Controlling Inflammation
Presenter: Jyothsna Visweswaraiah, PhD, Director, Biotherapeutics Drug Creation
Session: Track 1, Novel Bispecifics, Multi-specifics and Therapeutic Combinations
Time: 5:45 – 6:15 p.m. PT
Poster: Design and screening of FcγRIIb selective Fc domains to enhance checkpoint agonism and treat immune mediated diseases
Author: Allison Colthart, PhD, Principal Scientist Drug Creation
Location: San Diego, CA
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X (formerly Twitter) @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
This links to an external website.